Stocks
Goldman Sachs Slashes Ultragenyx Pharmaceutical Target Price to $19
The Goldman Sachs Group has issued a pessimistic forecast for Ultragenyx Pharmaceutical's (NASDAQ:RARE) stock price. The firm has cut its target price from $28 to $19, indicating a potential upside of 21.10% from the previous close.
According to the report, analysts at Goldman Sachs have a 'neutral' rating on RARE's stock. Several other brokerages have also weighed in on RARE, with some maintaining positive ratings despite significant target reductions.
The firm's revenue for the quarter came in at $214 million, beating analyst expectations of $183.08 million. However, the biopharmaceutical company reported a net margin of -81.79% and a negative return on equity of 1,024.42% for the quarter.